Nov. 12 (Bloomberg) -- Procter & Gamble Co., the world’s largest consumer-products maker, and Teva Pharmaceutical Industries Ltd. won European Union approval for a joint venture to sell over-the-counter medicines.
The European Commission said the deal didn’t raise competition concerns because the combined market share for pain killers and cough medicine would remain relatively low and P&G would continue to face rivalry. It said it approved the deal as P&G’s proposed acquisition of Teva’s over-the-counter business.
Paul Williams, a spokesman for Teva, said P&G will have a 51 percent stake in the venture, PGT Healthcare, and Teva will hold the remainder.
“This is a joint initiative that has ongoing involvement from the two parties,” Williams said in by e-mail.
To contact the reporter on this story: Aoife White in Brussels at firstname.lastname@example.org
To contact the editor responsible for this story: Anthony Aarons at email@example.com